Word

PROTEINA

Status

Pending

Status Code

641

Status Date

Monday, August 21, 2023

Serial Number

97655467

Mark Type

4000

Filing Date

Monday, October 31, 2022

Trademark Owner History

Proteina Co., Ltd.

Classifications

9 Biochip; Biochip analyzing apparatus; biochip sensors; Cell chip inspection devices; Diagnostic apparatus for the detection of biomarkers for laboratory or research use; Protein analysis devices; Laboratory apparatus for analyzing biological pharmaceuticals; Scientific instruments for analyzing chemical and biological substances for the presence, absence, or quantity of target biologics and chemicals; Optical imaging apparatus and instruments for use in the study of proteins, peptides, DNA, aptamer, and RNA; Biosensors, namely, sensors for the purpose of scientific and diagnostic use for detecting the presence of multiple molecular substances; Diagnostic apparatus for the detection of proteins, DNA, and cells, not for medical purpose; Downloadable and recorded computer software for use in database generation, analysis, and management; Downloadable and recorded computer software for use in optical image and scientific data analysis; Downloadable computer software for use in the field of bioinformatics

44 Medical analysis for the diagnosis and treatment of persons; Medical analysis services for cancer diagnosis and prognosis; Provision of information regarding cancer prevention, screening, diagnosis, and treatment; Medical analysis services relating to cancer diagnoses; Analysis of human biometric data for medical purposes; Medical analysis services relevant to diagnoses, drug development, laboratory testing, and scientific research; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical diagnostic services for testing and analysis; Analysis of human tissue for medical treatment; information services relating to pharmaceuticals and medical products; Medical testing for diagnostic or treatment purposes; Medical testing services relating to the diagnosis and treatment of disease; Clinical medical consultation services, namely, collecting, reviewing, analyzing, and reporting clinical data; Medical laboratory services for the analysis of samples taken from patients; Medical analysis services relating to treatment of patients

10 Analyzers for analyzing immunological activity for scientific or medical purposes; Medical apparatus and instrument for diagnostic use, namely, for medical diagnostic testing in the fields of cell-based testing; Medical diagnostic apparatus for detecting cancer; Apparatus for analyzing drug compounds; Fluorescence images used for in vitro diagnostics; Immunoassay apparatus for detecting and analyzing biomarkers for medical diagnoses; Medical diagnostic apparatus for testing genomic materials, proteins, and cells relevant to diseases; Medical instruments for analyzing and identifying genomic materials, proteins, and cells; Medical diagnostic apparatus and instruments for detecting and analyzing diseases related to genetic abnormality, protein abnormality, abnormal expression of proteins, and abnormality in protein interaction signals; Apparatus for medical, clinical, and diagnostic uses by analyzing genomic materials, proteins, and cells; Computer displays and computer monitors and controllers used in direct association with medical diagnosis apparatuses during the process of diagnosis of a condition in an individual; Immunochemical testing apparatus for analyzing genomic materials, proteins, and cells; Automatic analyzers for disease diagnosis through inspection of genomic materials, proteins, and bio-samples; Apparatus for testing genomic materials, proteins, and cells relevant to diseases; Apparatus for tumor diagnosis; Medical apparatus for testing genomic materials, proteins, and cells relevant to diseases; Apparatus for analyzing images for medical use, namely, fluorescence imaging apparatus for medical purpose; Medical diagnostic apparatus for analyzing and measuring genomic materials, proteins, and bio-samples; In vitro diagnostic devices for molecularly characterizing diseases related to genetic abnormality, protein abnormality, abnormal expression of proteins, and abnormality in protein interaction signals

42 Early evaluation of new pharmaceuticals; Discovery and development of new pharmaceuticals; Scientific research for medical purposes in the area of cancerous diseases; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Assessment of the efficiency of pharmaceuticals; Medical research laboratory services for predicting disease; Pharmaceutical testing; Pharmaceutical research services; Provision of information regarding testing, inspection, and research of pharmaceutical products; Pharmaceutical product evaluation; Scientific research into medicine, health, and pharmacology; Human tissue analysis for the purpose of medical research; Design of devices intended for protein analysis; Protein analysis; Development of devices intended for protein analysis; Scientific and technological services, namely, scientific research in the field of biopharmaceuticals; Development of medical diagnostic instruments; Technological research in the field of biopharmaceuticals; Technical data analysis services for genomic and proteomic materials; Materials analysis; Development of computer software for big data processing; Biomedical research services; Biological research; Pharmaceutical research and development; Medical and scientific research, namely, conducting clinical trials by proxy; Medical and scientific research, namely, conducting clinical studies of medicines; Pharmaceutical product evaluation; Scientific research services for medical purposes; Design of medical diagnostic apparatus and instruments; Development of computer software for use with medical equipment; Laboratory research services relating to pharmaceuticals; Design and development of image processing software;

Trademark Events

Feb 20, 2024

Teas Response To Office Action Received

Feb 20, 2024

Amendment To Use Processing Complete

Feb 20, 2024

Use Amendment Filed

Feb 20, 2024

Teas Amendment Of Use Received

Nov 20, 2023

Application Extension Granted/Receipt Provided

Nov 20, 2023

Application Extension To Response Period - Received

Aug 21, 2023

Notification Of Non-Final Action E-Mailed

Aug 21, 2023

Non-Final Action E-Mailed

Aug 21, 2023

Non-Final Action Written

Aug 14, 2023

Assigned To Examiner

Nov 16, 2022

New Application Office Supplied Data Entered

Nov 3, 2022

New Application Entered